Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baxdrostat plus dapagliflozin for prevention of heart failure events and cardiovascular death in high-risk patients
CTR20250951Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF), cardiac morbidity, type 2 diabetes mellitus (T2DM) and 1 more comparing Baxdrostat plus dapagliflozin with Placebo plus dapagliflozin (2 arms). Primary endpoint: Time to first occurrence of composite endpoint. Started Jun 2025; status: active.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
heart failure (HF)cardiac morbiditytype 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on CTR20250951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250951.